Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 114,644 Shares of Johnson & Johnson (NYSE:JNJ)

Key Points

• The Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its stake in Johnson & Johnson by 14.8%, now holding 658,969 shares worth approximately $109.28 million.
• Wall Street analysts have a mixed perspective on the stock, with an average rating of "Moderate Buy" and recent price targets ranging from $165.00 to $190.00.
• Johnson & Johnson declared a quarterly dividend of $1.30 per share, resulting in an annualized yield of 3.0%, with a payout ratio of 55.61%.

Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 14.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 658,969 shares of the company's stock after selling 114,644 shares during the period. Johnson & Johnson comprises 1.3% of Fjarde AP Fonden Fourth Swedish National Pension Fund's portfolio, making the stock its 11th largest position. Fjarde AP Fonden Fourth Swedish National Pension Fund's holdings in Johnson & Johnson were worth $109,283,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Mitsubishi UFJ Asset Management UK Ltd. lifted its position in Johnson & Johnson by 200.0% during the first quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 4,500 shares of the company's stock valued at $746,000 after purchasing an additional 3,000 shares during the last quarter. American Money Management LLC raised its holdings in Johnson & Johnson by 1.1% in the first quarter. American Money Management LLC now owns 37,827 shares of the company's stock worth $6,273,000 after purchasing an additional 423 shares in the last quarter. Francis Financial Inc. purchased a new position in shares of Johnson & Johnson in the 1st quarter worth approximately $227,000. William B. Walkup & Associates Inc. boosted its stake in Johnson & Johnson by 4.7% in the 1st quarter. William B. Walkup & Associates Inc. now owns 12,674 shares of the company's stock worth $2,102,000 after purchasing an additional 574 shares in the last quarter. Finally, E Fund Management Co. Ltd. boosted its position in Johnson & Johnson by 15.6% in the first quarter. E Fund Management Co. Ltd. now owns 32,801 shares of the company's stock valued at $5,440,000 after buying an additional 4,425 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on JNJ shares. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Leerink Partners downgraded shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Barclays raised their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Finally, Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $174.50.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded up $2.04 on Friday, reaching $176.76. The stock had a trading volume of 9,476,237 shares, compared to its average volume of 8,427,234. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $177.27. The business's 50-day moving average price is $160.85 and its two-hundred day moving average price is $158.16. The stock has a market cap of $425.70 billion, a P/E ratio of 18.90, a price-to-earnings-growth ratio of 2.23 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the firm earned $2.82 EPS. The company's revenue for the quarter was up 5.8% on a year-over-year basis. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.